Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
2003 1
2004 1
2005 5
2006 1
2007 2
2009 2
2010 2
2011 5
2012 2
2013 1
2014 3
2015 1
2016 2
2017 5
2018 2
2019 1
2020 4
2021 4
2022 8
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Developmental and epileptic encephalopathy, 76"
Page 1
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Devinsky O, et al. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. N Engl J Med. 2018. PMID: 29768152 Free article. Clinical Trial.
BACKGROUND: Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with t …
BACKGROUND: Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated …
Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L, Guerrini R, Zuberi SM, Nabbout R, Riney K, Shore S, Agarwal A, Lock M, Farfel GM, Galer BS, Gammaitoni AR, Davis R, Gil-Nagel A. Knupp KG, et al. JAMA Neurol. 2022 Jun 1;79(6):554-564. doi: 10.1001/jamaneurol.2022.0829. JAMA Neurol. 2022. PMID: 35499850 Free PMC article. Clinical Trial.
IMPORTANCE: New treatment options are needed for patients with Lennox-Gastaut syndrome (LGS), a profoundly impairing, treatment-resistant, developmental and epileptic encephalopathy. OBJECTIVE: To evaluate the efficacy and safety of fenfluramine in patients w …
IMPORTANCE: New treatment options are needed for patients with Lennox-Gastaut syndrome (LGS), a profoundly impairing, treatment-resistant, …
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Lattanzi S, Trinka E, Russo E, Del Giovane C, Matricardi S, Meletti S, Striano P, Damavandi PT, Silvestrini M, Brigo F. Lattanzi S, et al. Drugs. 2023 Oct;83(15):1409-1424. doi: 10.1007/s40265-023-01936-y. Epub 2023 Sep 11. Drugs. 2023. PMID: 37695433 Free PMC article.
BACKGROUND: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant, lifelong seizures. ...Any randomized, controlled, double- or single-blinded, parallel-group study comparing at least one ASM therap …
BACKGROUND: Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant …
Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
Knupp KG, Scheffer IE, Ceulemans B, Sullivan J, Nickels KC, Lagae L, Guerrini R, Zuberi SM, Nabbout R, Riney K, Agarwal A, Lock M, Dai D, Farfel GM, Galer BS, Gammaitoni AR, Polega S, Davis R, Gil-Nagel A. Knupp KG, et al. Epilepsia. 2023 Jan;64(1):139-151. doi: 10.1111/epi.17431. Epub 2022 Nov 9. Epilepsia. 2023. PMID: 36196777 Free PMC article. Clinical Trial.
METHODS: Eligible patients with LGS who completed a 14-week phase 3 randomized clinical trial enrolled in an open-label extension (OLE; NCT03355209). ...SIGNIFICANCE: Patients with LGS experienced sustained reductions in drop seizure frequency on fenfluramine …
METHODS: Eligible patients with LGS who completed a 14-week phase 3 randomized clinical trial enrolled in an open-label …
The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.
Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, O'Callaghan FJ, Verity CM, Osborne JP; United Kingdom Infantile Spasms Study. Lux AL, et al. Lancet Neurol. 2005 Nov;4(11):712-7. doi: 10.1016/S1474-4422(05)70199-X. Lancet Neurol. 2005. PMID: 16239177 Clinical Trial.
We sought to assess whether early control of spasms is associated with improved developmental or epilepsy outcomes. METHODS: Infants enrolled in the United Kingdom Infantile Spasms Study (UKISS) were randomly assigned hormone treatment (n=55) or vigabatrin (n …
We sought to assess whether early control of spasms is associated with improved developmental or epilepsy outcomes. METHODS: I …
Levetiracetam efficacy in PCDH19 Girls Clustering Epilepsy.
Sadleir LG, Kolc KL, King C, Mefford HC, Dale RC, Gecz J, Scheffer IE. Sadleir LG, et al. Eur J Paediatr Neurol. 2020 Jan;24:142-147. doi: 10.1016/j.ejpn.2019.12.020. Epub 2020 Jan 3. Eur J Paediatr Neurol. 2020. PMID: 31928905
BACKGROUND: PCDH19 Girls clustering epilepsy (GCE) has a phenotypic spectrum that includes developmental and epileptic encephalopathy. ...DISCUSSION: Levetiracetam was effective in two cohorts of females with PCDH19-GCE where 42% and 76% of fema …
BACKGROUND: PCDH19 Girls clustering epilepsy (GCE) has a phenotypic spectrum that includes developmental and epileptic …
Epileptic spasms: A South African overview of aetiologies, interventions, and outcomes.
Raga SV, Essajee F, Solomons R, Van Toorn R, Wilmshurst JM. Raga SV, et al. Dev Med Child Neurol. 2023 Apr;65(4):526-533. doi: 10.1111/dmcn.15433. Epub 2022 Oct 13. Dev Med Child Neurol. 2023. PMID: 36229895 Free article.
A lead time to treatment (LTTT) of less than 1 month was more likely in the epileptic encephalopathy/developmental and epileptic encephalopathy (DEE) group: 58 out of 92 (63%), compared to 28 out of 76 (37%) of those with developmental …
A lead time to treatment (LTTT) of less than 1 month was more likely in the epileptic encephalopathy/developmental and …
Persistent hyperinsulinaemic hypoglycaemia in infancy.
Shah P, Demirbilek H, Hussain K. Shah P, et al. Semin Pediatr Surg. 2014 Apr;23(2):76-82. doi: 10.1053/j.sempedsurg.2014.03.005. Epub 2014 Mar 15. Semin Pediatr Surg. 2014. PMID: 24931352 Review.
It is extremely important to recognise this condition early and institute appropriate management to prevent significant brain injury leading to complications like epilepsy, cerebral palsy and neurological impairment. ...Fluorine-18-l-3,4-dihydroxyphenylalanine posit …
It is extremely important to recognise this condition early and institute appropriate management to prevent significant brain injury …
Use of ketogenic dietary therapy for drug-resistant epilepsy in early infancy.
Armeno M, Calligaris S, Gagiulo D, Cresta A, Vaccarezza MM, Diez CG, Alberti MJ, Viollaz R, Vilavedra F, Caraballo RH. Armeno M, et al. Epilepsia Open. 2024 Feb;9(1):138-149. doi: 10.1002/epi4.12836. Epub 2023 Nov 20. Epilepsia Open. 2024. PMID: 37759424 Free PMC article.
The aim of this study was to evaluate effectiveness, safety, and survival of infants younger than 3 months of age with drug-resistant epilepsy in whom KDT was used. METHODS: A retrospective study was conducted to evaluate neonates and infants younger than 3 months who star …
The aim of this study was to evaluate effectiveness, safety, and survival of infants younger than 3 months of age with drug-resistant epi …
Proper Therapy Selection Improves Epilepsy Outcomes in Patients With Multilobar Sturge-Weber Syndrome.
Sugano H, Iimura Y, Suzuki H, Mitsuhashi T, Ueda T, Nishioka K, Tamrakar S, Karagiozov K, Nakajima M. Sugano H, et al. Pediatr Neurol. 2023 Jun;143:6-12. doi: 10.1016/j.pediatrneurol.2023.02.011. Epub 2023 Feb 24. Pediatr Neurol. 2023. PMID: 36934517 Free article.
Surgical indications included (1) antiepileptic drug (AED)-resistant seizures; (2) developmental delay; and (3) cortical atrophy. Twenty-nine patients were classified in the medical treatment group (MTG), and 21 patients were in the surgical treatment group (STG). ...CONCL …
Surgical indications included (1) antiepileptic drug (AED)-resistant seizures; (2) developmental delay; and (3) cortical atrophy. Twe …
56 results